ICCC
ImmuCell Corporation6.04
-0.10-1.63%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
54.64MP/E (TTM)
21.57Basic EPS (TTM)
0.28Dividend Yield
0%Recent Filings
8-K
8-K
Q3 sales dip 8%
ImmuCell Corporation reported preliminary unaudited sales of $5.5 million for Q3 2025, down 8% from $6.0 million in Q3 2024, while nine-month sales rose 7% to $20.0 million amid inventory restocking. Backlog depletion lifted earlier volumes, but sales softened as expected in the second half. Sales teams push to regain market share. Re-Tain® advances in studies, eyeing mastitis treatment without milk discard.
8-K
ImmuCell appoints new CEO
ImmuCell Corporation elected Olivier te Boekhorst as President and CEO, effective November 1, 2025, replacing Michael F. Brigham, who will transition to Special Advisor for two months while remaining on the board. Te Boekhorst, with deep experience from IDEXX Laboratories in livestock diagnostics, joins at a $450,000 base salary, up to $400,000 annual bonus tied to financial targets, and $100,000 signing bonus, plus stock options for about 161,673 shares vesting over three years. This leadership shift aims to drive growth in First Defense sales and Re-Tain development amid antibiotic-free animal health opportunities. Yet risks linger in meeting performance goals.
8-K
Line of credit extended
ImmuCell Corporation extended its $1 million line of credit with Maine Community Bank through September 11, 2026, maintaining variable interest at the National Prime Rate. This amendment, effective August 20, 2025, preserves all original terms while securing ongoing liquidity. Extension bolsters financial flexibility amid operations.
8-K
ImmuCell Q2 sales up 18%
ImmuCell Corporation reported robust Q2 2025 results, with product sales surging 18% to $6.4 million versus the prior year, driving a 44% gross margin and $502,000 net income—flipping last year's $1.5 million loss. Cash swelled to $6.0 million, bolstering a healthier balance sheet amid cleared order backlogs. Re-Tain® advances via field trials, yet development costs are trimming. Profitability rebounded sharply.
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
CVM
Cel-Sci Corporation
5.90-0.10
IMA
ImageneBio, Inc.
6.25+0.08
IMNN
Imunon, Inc.
3.88-0.09
IMRX
Immuneering Corporation
5.74-0.04
IMTX
Immatics N.V.
10.09+0.11
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
IMUX
Immunic, Inc.
0.60-0.01
ISCO
International Stem Cell Corp.
0.14-0.03